Las Vegas, NV -- (SBWIRE) -- 09/26/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: Velti Plc(NASDAQ:VELT), Omeros Corporation(NASDAQ:OMER), Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX), Generex Biotechnology Corporation(OTCMKTS:GNBT)
Velti Plc(NASDAQ:VELT) ended higher +4.33% and complete the day at $0.388. The total number of shares changed hands during the day was 2.22 million. After opening at $0.37, the stock hit as high as $0.42. However, it traded between $0.33and $9.11 over the last twelve months. Velti plc engages in the provision of mobile marketing and advertising technology and solutions for brands, advertising agencies, mobile operators, and media companies primarily in Europe, the Americas, Asia, and Africa.
For How Long VELT will Fight for Profitability? Read This Trend Analysis report
Omeros Corporation(NASDAQ:OMER) closed yesterday at $9.37, a +3.42% increase. Around 2.15 million shares were traded, beating an-average trading volume of 1.20 million shares. The company is now valued at around $279.68 million. Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.
For How Long OMER’s Gloss will Attract Investors? Find out via this report
Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX) moved +1.30 percent higher at $3.12 and traded between $0.37 and $3.24 after opening the day at $3.17 . Its performance over the last five days remained +28.4%, which stands at +145.67% for a month. Going back further than one month, 1-year performance after recent close was +617.24%. Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
Will CPRX Continue To Move Higher? Find Out Here
Generex Biotechnology Corporation(OTCMKTS:GNBT)’s shares drop,losing -4.23 percent to close at $0.0317. The stock is up around +26.8% this year and -53.38% for the last 12 months. Around 2.07 million shares changed hands yesterday, lower from an-average trading volume of 2.09 million shares. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Will GNBT Get Buyers Even After The Recent Rally? Find Out Here
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)